Hi Everyone! I would like to know about the Most Used Oncology CPT Codes. If I can have access to PDF, this would be great.
Here is the forum reply:
Hey @HenryBrick! Great question, and you are definitely not alone in looking for a consolidated reference for this. Oncology billing in 2026 is more nuanced than ever, so let me break this down properly for you. 
Why Oncology CPT Codes Matter More in 2026
2026 is one of the most significant years for oncology CPT restructuring, particularly in radiation oncology and supportive chemotherapy care. The AMA revises codes annually, and this year several radiation delivery codes were updated while new superficial therapy codes were introduced. A single coding error can trigger medical claim audits and lead to penalties, so staying current is not optional for any practice that wants to protect its revenue.
Most Used CPT Codes by Category
Evaluation and Management (E/M)
99213, 99214, and 99215 remain the most billed E/M codes in oncology outpatient settings. Payers heavily scrutinize these when billed alongside infusion or chemo codes. Without clear assessment and decision-making documentation, claims get denied as bundled. Always append Modifier 25 when billing an E/M on the same date as a procedure.
Chemotherapy Administration
These are the workhorses of oncology billing:
96413 covers initial IV infusion of a chemotherapy agent (first hour). This intravenous approach is the most widely used because it ensures quick drug absorption in the bloodstream.
96415 is the add-on code for each additional hour of IV infusion beyond the first. This is where infusion time documentation gaps cause the most denials.
96409 covers IV push administration for a single chemotherapy drug, while 96411 is the sequential add-on for additional drugs at the same session.
A common RAC audit trigger is duplicate chemotherapy infusion billing, such as 96413 being billed multiple times for a single infusion episode. The best defense is an infusion log with entry and exit clock times, the RN signature, and drug lot numbers for each unique infusion event.
Radiation Oncology
77427 covers radiation treatment management (typically reported per five fractions). This code uses ionizing radiation beams to destroy cancer cells by damaging DNA in cancerous cells.
77387 is the image guidance add-on. The OIG Work Plan for 2026 is specifically targeting 77387 being billed without the corresponding base code 77373, or without evidence that guidance was actually delivered, such as no daily physics note.
Pathology
CPT 88305 is the Level IV surgical pathology code used for microscopic examination of tissue specimens, and it is the most common code for routine biopsies in oncology.
HCPCS J-Codes for Drug Administration
J-codes are how you bill for the actual drugs. J9999 (not otherwise classified chemotherapy) should be your last resort. High-volume codes include J9035 (Bevacizumab), J9355 (Trastuzumab), and J9299 (Nivolumab), depending on your payer mix and therapeutic protocols. Always attach -JW or -JZ modifiers for drug wastage compliance, as this is now a standard payer expectation in 2026.
Three Denial Triggers to Watch in 2026
- Missing modifier documentation when billing E/M with chemotherapy on the same date
- Infusion time logs that do not capture clock-in and clock-out times for each drug
- Radiation add-on codes (like 77387) submitted without the base code and physics documentation
Want the PDF Reference?
Transcure has a solid oncology billing breakdown on their resource page at transcure.net that covers ICD-10 pairing, CPT hierarchy rules, and payer-specific nuances. Worth bookmarking for your coding team.
If you need a PDF cheat sheet specifically, drop a reply and I can point you to the right downloadable resource.
Hope this helps your team tighten up submissions! 
For your references:
Hey @HenryBrick Great timing on this question. 
Most threads here cover infusion codes or radiation, but almost nobody stops to talk about what 2026 actually changed structurally, and why that matters for your day to day claim submissions.
The Codes That Actually Move the Revenue Needle
The E/M series (99213 to 99215) still drives the highest volume for outpatient oncology visits. Under current CMS guidelines, E/M level selection is based on either Medical Decision Making or total time spent on the date of service, and that distinction is where a lot of practices are leaving money on the table by defaulting to 99213 out of habit.
For chemotherapy administration, 96413 (initial IV infusion, first hour) and 96415 (each additional hour) remain the two most billed codes in medical oncology. 96413 covers only the initial first hour of administration, and you report the add-on for each additional hour the provider administers the drug infusion. Simple enough in theory. In practice, missing clock documentation wipes out the add-on entirely.
What Actually Changed in 2026 That Most Practices Missed
Radiation treatment delivery is now billed by complexity level rather than technique, which is a major structural shift. Deleted codes include 77385, 77386, and 77014. Technical image guidance is now bundled into 77402 through 77412. If your system still uses those deleted codes, those claims will not pay in 2026.
Scalp cooling also got permanent Category I status this year. Codes 97007 through 97009 now require proper documentation for measurement, calibration, and timed cooling periods, and practices that have not updated their charge capture templates are already seeing rejected claims.
The Outsourcing Concern Nobody Wants to Say Out Loud
Here is where I want to be direct with this community. Outsourcing oncology billing is not inherently risky. Outsourcing it to the wrong vendor absolutely is. There are solid players in this space.
Neolytix covers o
- ncology and hematology coding well.
- AnnexMed has a strong handle on denial patterns.
- Quest National Services does good work on modifier compliance.
But the concern is real when a practice hands off something this technically demanding to a generalist billing company that also does primary care and dermatology claims in the same queue.
Because of the high cost of cancer care, insurers closely monitor oncology claims, and even a minor coding error can lead to revenue loss or compliance audits. That level of scrutiny requires a vendor whose coders actually live in oncology day to day. Transcure Oncology Billing Services is built specifically around this, with dedicated oncology RCM workflows rather than a shared generalist team. That specificity matters when your payer mix includes Medicare Advantage plans with aggressive bundling edits and prior auth requirements tied directly to your J-codes.
The right vendor does not just submit claims. They audit your coding before submission, track your denial patterns by payer, and flag code transitions like the 2026 radiation restructure before your revenue takes a hit. That is the standard worth holding any outsourcing partner to.
The 2026 update is not a routine refresh. Radiation oncology codes such as 77014 and 77385/77386 were deleted, and the old simple, intermediate, and complex terminology was removed in favor of updated service-level hierarchies. So a frequency-ranked list pulled from 2025 claims is a liability, not a cheat sheet. Your highest-volume radiation codes are exactly where deleted codes hide.
The more useful exercise is a gap analysis on your top code families. Pull your most-billed codes, flag every deletion lacking a direct replacement, and update documentation and vendor tools before submission.
Two other 2026 traps worth flagging. Single-dose drug claims now depend on correct JW and JZ wastage modifiers, and missing them drives predictable denials. Infusion hierarchy and documented start and stop times remain the other common failure point, since chemotherapy administration takes priority over therapeutic infusion and hydration.
The infusion codes everyone already knows, like 96413 for the initial hour and 96415 for each additional hour, are stable. The real 2026 risk sits in radiation delivery and drug wastage, not the codes most people memorize.
Quick reframe on the actual ask, then a 2026 trap that has not come up yet.
On the PDF: be a little careful what you wish for. A frequency-ranked cheat sheet is exactly the kind of thing that turned into a liability this year, because the radiation codes shifted underneath everyone. Any static list you download is only as good as the day it was published. If you want something that stays correct, the better move is to anchor your team to the living sources rather than a snapshot. AMA CPT for the code changes, the CMS NCCI edit files and MUE tables for unit caps and bundling, and the ASCO and ASTRO coding resources for the oncology-specific guidance. Those update on a schedule. A forum PDF does not.
The other thing worth saying out loud: there is no universal most-used list. Your top ten is a function of your service mix. A medical oncology infusion practice and a radiation center barely overlap on their highest-volume codes. The genuinely useful version of this exercise is to pull your own 837 data, rank by both claim frequency and denied dollars, and build the cheat sheet off that. The codes costing you the most in denials are the ones worth memorizing, not the ones that are simply common.
Now the trap nobody mentioned: biosimilars. Bevacizumab, trastuzumab, and rituximab all have multiple biosimilar versions, and each biosimilar carries its own HCPCS in the Q5xxx family rather than the reference J-code. So billing J9035 for a bevacizumab biosimilar, when the drug you actually dispensed maps to something like Q5107, is a clean denial every time. The dispensed NDC drives the code, not the molecule. If your charge capture is still pointing every bevacizumab to one J-code, that is a quiet and very fixable revenue leak.
Last layer, since wastage and clock times already got covered well above: watch your MUE unit caps and the NCCI bundling between administration codes. A correct code with too many units, or a chemo admin code that bundles into another on the same date, fails just as fast as a missing modifier. That is usually the denial bucket people discover last.